Kymera Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
KYMR Nasdaq 2830 www.kymeratx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kymera Therapeutics, Inc.

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says - Aug 10th, 2026 10:44 am
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments - Aug 6th, 2026 12:52 pm
Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR) - Aug 6th, 2026 1:15 am
Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary - Aug 5th, 2026 4:01 pm
Kymera Therapeutics Q2 Earnings Call Highlights - Aug 5th, 2026 11:04 am
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates - Aug 5th, 2026 6:15 am
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - Aug 5th, 2026 5:00 am
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls - Jul 30th, 2026 7:38 am
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More - Jul 30th, 2026 6:05 am
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026 - Jul 28th, 2026 2:01 pm
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer - Jul 27th, 2026 2:01 pm
Is Kymera Therapeutics Poised for a Breakthrough With KT-621? - Jul 24th, 2026 9:18 am
American Express, Biogen upgraded: Wall Street's top analyst calls - Jul 13th, 2026 7:41 am
Kymera's CEO Sold $6 Million in Stock After a 170% Run - Jul 12th, 2026 2:57 pm
Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Jul 9th, 2026 4:40 am
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader - Jul 7th, 2026 5:00 am
Alkami Technology, Diebold Nixdorf, and 3 More Stocks See Action From Activist Investors. - Jul 3rd, 2026 2:00 am
Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift - Jul 3rd, 2026 12:12 am
How Accelerated KT-621 Trial, Index Additions, and New Chair Will Impact Kymera Therapeutics (KYMR) Investors - Jul 2nd, 2026 7:08 pm
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug - Jul 1st, 2026 11:06 am